ClinicalTrials.gg
RecruitingNCT07166757Updated Dec 29, 2025

Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease

A Phase 1/2 interventional study of human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection in Parkinson Disease (PD), sponsored by XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
57th of 211
90 · median 47
Started
2025
with 32 others
Phase 1/2
10 of 279
5 open now
Primary completion
2028-03
later than 111 of 134 live
Registered
222nd of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 57th largest by planned enrollment of the 211 interventional ones that give a count, is one of 33 that started in 2025, is one of 10 in phase 1/2, reaches primary completion later than 111 of the 134 other live ones, and was the 222nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This study is a Phase I/II clinical study to evaluate the safety, tolerability, and efficacy of XS411 in the treatment of EOPD. The study consists of two phases: Phase I and Phase II.

Phase I study is planned to be conducted in patients with EOPD, using a single-arm, open-label, traditional " 3+3 " dose-escalation design, aiming to investigate the safety, tolerability and preliminary efficacy of XS411 in the treatment of EOPD and to determine the RP2D.

Phase I study enrolls 6-12 patients with EOPD. Two dose cohorts (3-6 patients/dose cohort) are planned: 9×10⁶ cells /patient and 1.8 ×10⁷ cells /patient. Each participant will receive a single injection of XS411. Each participant in each dose cohort will be observed for at least 28 days after dosing . If no DLTs occur and the investigator has no other safety concerns for that participant, the next participant in that dose cohort will be enrolled.

Phase II study is planned for patients with EOPD, using a randomized, double-blind, sham-controlled, parallel-group design . The study will investigate the efficacy and safety of XS411 in the treatment of EOPD . Phase II study currently plans to enroll 81 patients with EOPD. The patients will be randomly assigned in a 2:1 ratio to either the experimental or control group. Participants in the experimental group will receive a single injection of XS411 in combination with an immunosuppressant at the RP2D determined during the Phase I dose-escalation phase (which may be adjusted based on the Phase II study results). The control group will receive a sham procedure in combination with an immunosuppressant sham.

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old ≤ age of onset ≤ 50 years old, diagnosed with EOPD (meeting the MDS 2015 clinical diagnostic criteria for Parkinson's disease );
  • 18 years old ≤ age at enrollment ≤ 70 years old , male/female;
  • Disease duration ≥ 5 years;
  • Phase I: the modified Hoehn-Yahr grade in the off-phase is 3-4 (including the critical value) , and the modified Hoehn-Yahr grade in the on-phase is ≤3 ; Phase II: the modified Hoehn-Yahr grade in the off-phase is 2-4 (including the critical value) , and the modified Hoehn-Yahr grade in the on-phase is ≤3;
  • Off-period MDS -UPDRS-III score >30;
  • Positive L-dopa stress test;
  • The patient is unable to adequately control motor fluctuations even with a stable dose of medication recommended in the "Guidelines for the Treatment of Parkinson's Disease in China (Fourth Edition)" ;
  • Patients received stable doses of anti-PD drugs for at least 4 weeks before administration;
  • Able to accept surgical anesthesia, suitable for neurosurgery under anesthesia, and able to undergo brain CT /MRI examination;
  • Participants agree to postpone any other elective neurosurgery until the completion of the 24-month follow-up study;
  • Participants agreed not to participate in any other clinical studies within 24 months after dosing;
  • Participants or their legal representatives understand and comply with the research procedures, voluntarily participate and sign the ICF

Exclusion criteria

Exclusion Criteria:

  • Non-primary PD or Parkinson's superimposed syndromes ;
  • Patients are in the late stages of PD and are experiencing severe, disabling peak-dose dyskinesia or biphasic dyskinesia and/or unpredictable or widely fluctuating symptoms;
  • Have previously undergone neuronucleotomy, deep brain stimulation (DBS), striatal surgery, extrapyramidal surgery, stereotactic brain surgery, or other brain surgery; or who have undergone other surgical procedures that the investigator determined would affect participation in this study; or who have surgical
  • Patients currently receiving L-dopa intestinal instillation, apomorphine injection, or continuous daily infusion of anti-PD drugs;
  • Patients who had used botulinum toxin, phenol, subarachnoid injection of baclofen, or received interventional treatment for dystonia or spasticity within 6 months before medication;
  • Have used or drugs for a long time within 3 months before the screening visit;
  • Those who have received cell therapy before;
  • Patients who received electroconvulsive therapy within 30 days before administration;
  • Those who have received or plan to receive vaccines during the trial within 3 months before screening, such as vaccines for novel coronavirus pneumonia (COVID-19), influenza, herpes zoster, and pneumococcal vaccine;
  • Those with a history of mental illness who are judged by the researchers to be unsuitable for study participation; or those with severe suicidal ideation currently or within the year before screening or any history of suicide attempts within the past 2 years;
  • Those with active epilepsy or currently taking anti-epileptic drugs;
  • Those with a history of dementia or severe cognitive impairment; or those with obvious dementia or cognitive impairment at screening; dementia may affect participants' poor compliance, inability to accurately record diaries, and / or inability to sign the ICF;
  • Severe anxiety at screening;
  • Patients whose previous head CT/MRI examinations showed brain injuries such as brain trauma, cerebral vascular malformation, hydrocephalus, brain tumors, or abnormal brain imaging of the striatum and other brain regions, which significantly increased the surgical risk;
  • Those with uncontrolled diseases;
  • Patients with a history of severe cardiovascular and cerebrovascular diseases;
  • Patients with other serious systemic diseases;
  • During the screening period, patients have severe arthritis, limp, severe sequelae of stroke, severe osteoporosis, or a history of severe trauma within 1 month (such as hip or lower limb fractures), which may affect the study evaluation as assessed by the researchers;
  • Patients with malignant tumors or a history of malignant tumors;
  • Patients with active disseminated intravascular coagulation and obvious bleeding tendency within 3 months before signing the ICF, or patients who cannot stop taking antiplatelet drugs or other anticoagulants for at least 10 days before surgery;
  • Previous history of abnormal coagulation function;
  • Patients with lab result abnormalities during screening include;
  • Allergic to the drugs used in the study;
  • Are pregnant or breastfeeding, or plan to become pregnant during the study;
  • Female participants of fertile potential must have a positive pregnancy test result before dosing; female participants of fertile potential, or male participants who are not sterilized and whose partners are fertile, must not take effective measures from the time they sign the ICF until at least 24 months after dosing; female participants must not agree to not donate eggs from the time they sign the ICF until at least 24 months after dosing, and male participants must not agree to not donate sperm from the time they sign the ICF until at least 24 months after dosing;
  • Participants who are currently participating in other clinical trials, or have participated in other clinical studies and received intervention treatment within 1 month before administration;
  • Those who are considered by the researchers to have poor compliance;
  • Any other situation that the researcher deems to jeopardize the safety of the participants or affect the study evaluation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    9.0×10^6 cells / bilateral putamen

    Drug: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

  • Experimental
    1.8×10^7 cells / bilateral putamen

    Drug: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

Interventions

  • Drughuman allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

    5.0×10\^7 cells/mL, injection, once, 12 months

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of XS411 cell injection in the treatment of EOPD 28 days after administration

    To evaluate the safety and tolerability of XS411 cell injection in the treatment of EOPD through the incidence and severity of AEs/SAEs; the incidence of DLTs ; Vital signs, physical examination, 12-lead ECG, clinical laboratory tests, and head MRI. AEs occurring during the study will be graded according to CTCAE V5.0. DLT is defined as: (1) any CTCAE grade 3 or 4 AE related to the trial drug (including definitely related, probably related, and possibly related) occurring within 28 days of trial drug administration (such as grade 3 or 4 immune system diseases, infectious diseases, mental illnesses, kidney diseases, etc. related to the trial drug ); (2) Grade 2 AEs cannot be reduced to grade 1 or below within 14 days.

    Time frame: 28 days after treatment

Secondary outcomes

  1. To check the change on parameters in MDS-UPDRS questionnaire on Day 28, M3, M6, M9 and M12 to evaluate preliminary efficacy of XS411 cell injection.

    To evaluate the preliminary efficacy of XS411 cell injection in the treatment of EOPD through Changes from baseline in the scores of parts I, II, III, and IV of the MDS-UPDRS (individual scores, total score, and sum of scores II and III) after administration ;

    Time frame: 28 days, 3, 6, 9, and 12 months after administration

  2. Evaluation of the improvement of nigrostriatal dopamine transmitter system through PET-CT testing data change compared with baseline in M6 and M12 for 9 partipants

    To evaluation of the improvement of nigrostriatal dopamine transmitter system after XS411 cell injection in the treatment of EOPD through 18F-DOPA uptake in the striatum as shown by brain PET-CT at 6 and 12 months after administration compared with baseline.

    Time frame: 6 and 12 months after administration

  3. To check the change on parameters Hoehn-Yahr (modified) questionnaire on Day 28, M3, M6, M9 and M12 to evaluate preliminary efficacy of XS411 cell injection.

    To evaluate the preliminary efficacy of XS411 cell injection in the treatment of EOPD through Change from baseline in the Hoehn-Yahr (modified) Parkinson's disease rating scale score after administration ;

    Time frame: 28 days, 3, 6, 9, and 12 months after administration

  4. To check the change on parameters on OFF and ON-period change recorded in patient's diary on Day 28, M3, M6, M9 and M12 to evaluate preliminary efficacy of XS411 cell injection.

    To evaluate the preliminary efficacy of XS411 cell injection in the treatment of EOPD through Change from baseline in on-period without bothersome dyskinesia; Change from baseline in conscious off-period; Change from baseline in on-period without dyskinesia recorded in Patient's diary

    Time frame: 28 days, 3, 6, 9, and 12 months after administration

Other outcomes

  1. Evaluation of the improvement of nigrostriatal dopamine transmitter system after XS411 cell injection in the treatment of EOPD

    To evaluation of the improvement of nigrostriatal dopamine transmitter system after XS411 cell injection in the treatment of EOPD through PET-CT testing data change compared with baseline in M6 and M12 for 9 partipants in the striatum as shown by brain PET at 6 and 12 months after administration compared with baseline.

    Time frame: 6 and 12 months after administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2028, 30 months after the start.

Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Sep 10, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Mar 30, 2028
CompletionEst.
Mar 30, 2029
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07166757
Lead sponsor
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Sep 22, 2025
Primary completion
Mar 30, 2028 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Dec 29, 2025

Study contacts

Michael LEE
Contact
CEO@xellsmart.com
+86 21 64027719

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion